As alleged in a pending multidistrict litigation, Pharmacy Benefit Managers (PBMs), drug manufacturers and rebate aggregators have been colluding to artificially inflate the price of insulin, insulin related GLP-1 and diabetes medications for all downstream purchasers, leading to higher healthcare costs and insurance premiums. 

Leeds Brown Law is partnering with other nationally recognized antitrust class action law firms to demand accountability from major PBMs (like CVS Caremark, Express Scripts and OptumRx), major insulin and GLP-1 producers (like Eli Lilly, Novo Nordisk and Sanofi) and associated rebate aggregators. Several cases are already pending in the Multidistrict litigation (MDL) in the District of New Jersey styled In re Insulin Pricing Litigation (MDL No. 3080). Our team represents clients including self-funded payor organizations (like private Companies, Unions and Municipalities), pursuing claims under the federal Racketeer Influenced and Corrupt Organizations (RICO) Act, state unfair and deceptive acts, and common law. We estimate the damages could be extensive as, in some cases, the price fixing goes back more than two decades. The Courts have not decided whether any laws have been violated and the actions remain pending. 

Different from a traditional class action, MDLs combine individual plaintiffs or groups of plaintiffs into an organized procedure based on common legal or factual questions – even if the cases are filed all across the country. In some cases, individual companies or consumer can file their own complaint with the Court and collect damages based on their own losses. If you wish to have your claims or facts assessed by our team, please reach out. Time is of the essence as the case is moving forward.